Raymond James on Regenxbio Inc. (RGNX): 'we think FDA guidance is strongly supportive of HS D2S6 as a biomarker'
Tweet Send to a Friend
Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $29.00 price target on Regenxbio Inc. (NASDAQ: RGNX).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
